DRA SearchDRASearch

  • Search Home
  • DRA Home

DRX009326

FASTQ

SRA

Experiment Detail

Titledetection of miRNA extracted from the complete hydatidiform mole tissue
Design DescriptionBACKGROUND: The aim of this study was to identify complete hydatidiform mole (CHM)-pregnancy-associated microRNAs (miRNAs) in plasma.METHODS: First, by comparative analysis of miRNA expression profiles generated by next generation sequencing, we selected candidate CHM-pregnancy-associated miRNAs in plasma, which showed a higher expression in CHM tissues than in normal villous tissues, but no expression in blood cells. Then, expression levels of these miRNAs in CHM tissues and normal villous tissues were investigated to identify CHM-associated miRNAs with increased expression in CHM tissues compared with normal villous tissues. When the plasma concentration of cell-free CHM-associated miRNAs was significantly higher in CHM pregnant than in uncomplicated pregnant women, these miRNAs were identified as CHM associated. Finally, to identify CHM-pregnancy-associated miRNAs in plasma, circulating levels of CHM-associated miRNAs in plasma samples from CHM pregnant women were measured before and after evacuation.RESULTS: hsa-miR-520b, hsa-miR-520f and hsa-miR-520c-3p were selected as candidate CHM-pregnancy-associated miRNAs in plasma, and all of them were confirmed as CHM-associated miRNAs in tissue samples. All CHM-associated miRNAs were identified as CHM-associated in plasma. The circulating levels of all CHM-associated miRNAs in plasma were decreased significantly after evacuation (Wilcoxon signed rank test, P=0.001), suggesting that all of these miRNAs were pregnancy-associated molecules. CONCLUSIONS: We identified hsa-miR-520b, hsa-miR-520f and hsa-miR-520c-3p as CHM-pregnancy-associated miRNAs in plasma. Circulating levels of these miRNAs could be potential molecular markers for CHM pregnancy.
OrganismHomo sapiens

Library Description

Namelib-mother1-mole
StrategymiRNA-Seq
SourceTRANSCRIPTOMIC
SelectioncDNA
LayoutSINGLE
Construction Protocolpregnancy at 10 weeks gestation, and normal villous tissue from uncomplicated and singleton pregnant women who underwent artificial abortion at 10 weeks gestation. Blood samples (7 mL) were collected before evacuation and placed in tubes containing EDTA. CHM tissue samples after evacuation and normal villous tissue samples after artificial abortion were obtained immediately, and they were placed in RNAlater (Ambion, Austin, TX, USA). Using a mirVana miRNA Isolation Kit (Ambion), total RNA containing small RNA molecules was extracted from each sample immediately after sampling. Quality assessment and concentration measurements of total RNA, including small RNAs, were performed using a Bioanalyzer (Agilent Technologies, South Queensferry, UK) and a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), respectively. CHM was diagnosed by histopathological examination and its androgenetic origin (46,XX) was confirmed by DNA genotyping analysis including polymorphic marker of amelogenin gene (AmpFlSTR Identifiler PCR Amplification Kit; Applied Biosystems, Foster City, CA, USA). Normal villous samples were diagnosed by histopathological examination and the biparental origin (46,XX) of CHM was confirmed by the above DNA genotyping analysis. Gestational age for uncomplicated pregnant women was assessed using the crown-rump length (CRL) of fetus measured by ultrasonography, while that for molar pregnancy was decided by the last menstrual period.NGS was applied to a set of CHM tissue and corresponding blood samples from CHM pregnant women at 10 weeks gestation, and normal villous tissue samples from uncomplicated pregnant women at 10 weeks gestation to screen for candidate CHM-pregnancy-associated miRNAs in plasma. Small RNAs were extracted from each sample using a mirVana miRNA Isolation Kit (Ambion) according to the manufacturer?s instructions. RNA quality and the presence of small RNAs were verified on a Bioanalyser (Agilent Technologies). The concentration of RNA was measured on a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). After RNA quality was stringently assured, 5 ?g total RNA was used for small RNA library construction using a Small RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the manufacturer?s instructions. A pair of Illumina proprietary adapters was ligated to the 5? and 3? ends of RNAs, followed by reverse transcription. The small cDNA libraries were amplified by PCR with primers complementary to the adaptor sequences. Subsequently, the libraries were deep sequenced using an Illumina Genome Analyzer II and sequencing data were processed with the Illumina pipeline v1.4, according to the manufacturer?s instructions.

Platform

PlatformILLUMINA
Instrument ModelIllumina Genome Analyzer II

Processing

PipeSection
Step Index1
Prev Step IndexNIL
Program
Version

Spot Information

Number of Reads per Spots0
Spot Length51

Read Spec

Read Index 0
Read Label
Read ClassApplication Read
Read TypeForward
Base Coord1

Navigation

Submission DRA001009 FTP
Study DRP001051
Sample DRS009171
Run DRR010370 FASTQ SRA
Website policy | © DNA Data Bank of Japan